MX2021016058A - Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales. - Google Patents

Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales.

Info

Publication number
MX2021016058A
MX2021016058A MX2021016058A MX2021016058A MX2021016058A MX 2021016058 A MX2021016058 A MX 2021016058A MX 2021016058 A MX2021016058 A MX 2021016058A MX 2021016058 A MX2021016058 A MX 2021016058A MX 2021016058 A MX2021016058 A MX 2021016058A
Authority
MX
Mexico
Prior art keywords
antitumoral compounds
antitumoral
compounds
cancer
compound
Prior art date
Application number
MX2021016058A
Other languages
English (en)
Inventor
Marchante Maria Del Carmen Cuevas
Solloso Andres Francesch
Barrasa Valentin Martinez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MX2021016058A publication Critical patent/MX2021016058A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Un compuesto de la fórmula general I, en donde X, R1-R4 adopta varios significados, para usar en el tratamiento del cáncer. (ver formula).
MX2021016058A 2017-04-27 2019-10-25 Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales. MX2021016058A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382228 2017-04-27
EP17382497 2017-07-26

Publications (1)

Publication Number Publication Date
MX2021016058A true MX2021016058A (es) 2022-02-03

Family

ID=62063080

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019012812A MX2019012812A (es) 2017-04-27 2018-04-27 Compuestos antitumorales.
MX2021016054A MX2021016054A (es) 2017-04-27 2018-04-27 Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales.
MX2021016058A MX2021016058A (es) 2017-04-27 2019-10-25 Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2019012812A MX2019012812A (es) 2017-04-27 2018-04-27 Compuestos antitumorales.
MX2021016054A MX2021016054A (es) 2017-04-27 2018-04-27 Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales.

Country Status (37)

Country Link
US (5) US10538535B2 (es)
EP (5) EP3395821B1 (es)
JP (5) JP6501947B2 (es)
KR (3) KR102510975B1 (es)
CN (4) CN114736219B (es)
AU (4) AU2018260314C1 (es)
BR (1) BR112019022282A2 (es)
CA (1) CA3061518A1 (es)
CL (1) CL2019003057A1 (es)
CO (1) CO2019011967A2 (es)
CY (3) CY1121884T1 (es)
DK (5) DK3395821T3 (es)
EC (1) ECSP19083967A (es)
ES (5) ES2740073T3 (es)
FI (3) FI3615544T3 (es)
HK (2) HK1255941B (es)
HR (5) HRP20230433T1 (es)
HU (5) HUE063736T2 (es)
IL (3) IL270153B2 (es)
JO (1) JOP20190254A1 (es)
LT (5) LT4101855T (es)
MA (2) MA44021B1 (es)
MD (5) MD3615544T2 (es)
ME (2) ME03466B (es)
MX (3) MX2019012812A (es)
MY (1) MY198004A (es)
PH (1) PH12019550224A1 (es)
PL (5) PL3615544T3 (es)
PT (2) PT3395820T (es)
RS (5) RS59174B1 (es)
SG (2) SG11201909841RA (es)
SI (5) SI3615544T1 (es)
TN (2) TN2019000211A1 (es)
TW (3) TWI807411B (es)
UY (1) UY37706A (es)
WO (1) WO2018197663A1 (es)
ZA (1) ZA201907119B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190254A1 (ar) * 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
JOP20220118A1 (ar) * 2019-11-21 2023-01-30 Pharma Mar Sa طرق لعلاج سرطان الرئة للخلايا الصغيرة بصيغ من لوربينيكتيدين
CN115427081A (zh) 2020-04-21 2022-12-02 法马马有限公司 药物抗体共轭物
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
CN117295499A (zh) 2021-05-19 2023-12-26 法马马有限公司 海鞘素的给药方案
WO2024186263A1 (en) * 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3205220A (en) 1961-10-26 1965-09-07 Lilly Co Eli Leurosidine and leurocristine and their production
US4762949A (en) 1979-06-20 1988-08-09 University Of Illinois Foundation Acyl and carbamimidoyl alkanediamines
GB2058047B (en) 1979-07-11 1983-09-21 Asahi Chemical Ind Amides and amidines
FR2461995A1 (fr) 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US5137870A (en) 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
US4782135A (en) 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4548814A (en) 1980-12-18 1985-10-22 The Board Of Trustees Of The University Of Illinois Composition of matter and process
JPS5922518A (ja) 1982-07-29 1984-02-04 余合住金産業株式会社 洋服タンス
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
HU201672B (en) 1984-12-28 1990-12-28 Conpharm Ab Process for producing pharmaceutical compositions comprising podophyllotoxin
US4644072A (en) 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
DE3684868D1 (de) 1985-09-20 1992-05-21 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US4731377A (en) 1986-01-31 1988-03-15 Harbor Branch Oceanographic Institute, Inc. Antitumor cyclic peroxides
AU589282B2 (en) 1986-06-09 1989-10-05 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4737510A (en) 1986-09-30 1988-04-12 The Board Of Trustees Of The University Of Illinois Bioactive metabolites from the caribbean sponge agelas coniferin
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4847246A (en) 1987-09-11 1989-07-11 Wilson George R Antiviral compositions derived from fireflies and their methods of use
FR2623504B1 (fr) 1987-11-25 1990-03-09 Adir Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
DE68903907T2 (de) 1988-09-05 1993-06-09 Sankyo Co Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
WO1990005731A1 (en) 1988-11-24 1990-05-31 University Of Queensland Cytotoxic macromolecules
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
CA2007507C (en) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
US5053559A (en) 1989-12-29 1991-10-01 Oxaco S.A. Cleavage of 1,2,4-trioxanes
KR910014122A (ko) 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
GB9212000D0 (en) 1992-06-05 1992-07-15 Univ Madrid Complutense New synthetic antitumoral compound
EP0655066A1 (en) 1992-08-12 1995-05-31 PHARMACIA & UPJOHN COMPANY Protein kinase inhibitors and related compounds combined with taxol
US5756734A (en) 1992-09-11 1998-05-26 Pharmamar, S.A. Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe
ES2059259B1 (es) 1992-09-22 1995-10-01 Pharma Mar S A Pharmar Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral.
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302044D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Cytotoxic compounds i
US5569757A (en) 1993-03-30 1996-10-29 Rinehart; Kenneth L. 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1
GB9308111D0 (en) 1993-04-20 1993-06-02 Pharma Gen S A Active compound from a stonge
US5556777A (en) 1993-09-09 1996-09-17 Pharmamar, S.A. Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5514708A (en) 1994-02-18 1996-05-07 Pharmamar, S.A. Cytotoxic metabolites from Myriapora truncata
US5681813A (en) 1994-04-06 1997-10-28 Pharma Mar, S.A. Thiodepsipeptide isolated from a marine actinomycete
ES2100124B1 (es) 1994-08-01 1998-04-01 Pharma Mar Sa Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral.
US5514705A (en) 1994-09-07 1996-05-07 Pharmamar, S.A. Epidioxymanadic acids A and B
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
GB9422946D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Antineoplastic cyclolignan derivatives
GB9504662D0 (en) 1995-03-08 1995-04-26 Pharma Mar Sa Antitumour isocoumarins
US20010039041A1 (en) 1995-06-07 2001-11-08 Pharma Mar, S.A. Immunosuppressive sesbanimide compositions and methods of treatment using same
US5661175A (en) 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US5852033A (en) 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
GB9608010D0 (en) 1996-04-18 1996-06-19 Pharma Mar Sa Trunkamide A
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
WO1998017302A1 (en) 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Total synthesis of the amino hip analogue of didemnin a
CA2269881A1 (en) 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Semi-synthetic studies toward didemnin analogues
GB9622427D0 (en) 1996-10-28 1997-01-08 Pharma Mar Sa Antimalarial drugs
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US6028077A (en) 1997-04-15 2000-02-22 Rinehart; Kenneth L. Crambescidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
US6107520A (en) 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
USRE38793E1 (en) 1997-04-15 2005-09-06 Rinehart Kenneth L Spisulosine compounds
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
AUPO656597A0 (en) 1997-05-02 1997-05-29 Australian National University, The Preparation of therapeutic compounds
JP4327260B2 (ja) 1997-05-07 2009-09-09 フアルマ・マル・エセ・ア Ｌ型カルシウムチャンネルエンハンサーとしてのアプリジン
GB9723206D0 (en) 1997-11-03 1998-01-07 Inst Biomar Sa New cytotoxic pyridoacridine alkaloids
GB9727301D0 (en) 1997-12-23 1998-02-25 Inst Biomar Sa Asmarine A and B: New cytotoxic alkaloids
US6420357B1 (en) 1997-12-23 2002-07-16 Instituto Biomar, S.A. Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge
GB9801741D0 (en) 1998-01-27 1998-03-25 Inst Biomar Sa New cytotoxic tris (oxazole)-containing macrolides
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
IL138856A0 (en) 1998-04-06 2001-10-31 Univ Illinois Semi-synthetic ecteinascidins
US6656948B2 (en) 1998-04-29 2003-12-02 Universidad Complutense De Madrid Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system
EP1076486B1 (en) 1998-05-05 2005-08-31 Pharma Mar, S.A. Culture of sessile marine animals
US6316214B1 (en) 1998-05-11 2001-11-13 The Board Of Trustees Of The University Of Illinois ETM-775 metabolite of ecteinascidin 743
GB9810998D0 (en) 1998-05-21 1998-07-22 Univ Madrid Complutense Antitumour 1,5-diazaanthraquinones
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB9915069D0 (en) 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
WO2001035974A2 (en) 1999-11-15 2001-05-25 Pharma Mar S.A. Aplidine treatment of cancers
AU783562B2 (en) 2000-01-19 2005-11-10 Trustees Of Columbia University In The City Of New York, The Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
KR20020092958A (ko) 2000-02-16 2002-12-12 파르마 마르.에스.에이. 항종양 활성을 가진 옥시- 및 아미노-치환된테트라하이드로푸릴 유도체
US20030187075A1 (en) 2000-03-20 2003-10-02 Junichi Tanaka Keith Sponge antitumor compounds
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
MXPA02009943A (es) 2000-04-07 2003-04-25 Univ Pennsylvania Analogos de tamandarin y didemnin y metodos para hacerlos y usarlos.
PT1280809E (pt) 2000-04-12 2005-11-30 Pharma Mar Sa Derivados antitumorais de ecteinascidina
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
GB0010799D0 (en) 2000-05-04 2000-06-28 Inst Biomar Sa Stolonoxides
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0011927D0 (en) 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
AU2001262518B2 (en) 2000-06-06 2006-10-26 Pharma Mar, S.A. Antitumoral compounds
GB0016020D0 (en) 2000-06-29 2000-08-23 Inst Biomar Sa New polyciclic xanthones and their use
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
ES2327210T3 (es) 2000-07-11 2009-10-27 Pharma Mar, S.A. Derivados de variolina como agentes anticancerigenos.
CN1241658C (zh) 2000-07-13 2006-02-15 普罗里森姆股份有限公司 一种在存活对象的体内施加能量的装置
GB0019117D0 (en) 2000-08-03 2000-09-27 Univ Barcelona Derivatives of variolin B
AU9402401A (en) 2000-10-12 2002-04-22 Pharma Mar Sa Treatment of cancers
IL155273A0 (en) 2000-10-12 2003-11-23 Pharma Mar Sa Pharmaceutical compositions comprising an aplidine compound
DK1330258T3 (da) 2000-10-31 2006-05-22 Pharma Mar Sa Kahalalid F-formulering
CN100374162C (zh) 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
WO2002058688A1 (de) 2001-01-24 2002-08-01 Mestex Ag Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen
KR20030071853A (ko) 2001-01-25 2003-09-06 브리스톨-마이어스스퀴브컴파니 에포틸론 유사체를 함유한 비경구용 제제
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
GB0105745D0 (en) 2001-03-08 2001-04-25 Pharma Gen S A Immobilisation of ligands
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
GB0116966D0 (en) 2001-07-11 2001-09-05 Pharma Mar Sa Anittumoral compounds
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
US20050004018A1 (en) 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
AU2002334203C1 (en) 2001-10-19 2008-10-09 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
EP1435991B1 (en) 2001-10-19 2008-10-15 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0217638D0 (en) 2002-07-30 2002-09-11 Pharma Mar Sa Total synthesis of myriaporones
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
GB0218816D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa Antitumoral analogs of lamellarins
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
US20040033940A1 (en) 2002-08-16 2004-02-19 Pharma Mar, S.A. Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
JP4430009B2 (ja) 2002-10-18 2010-03-10 ファーマ・マール・エス・アー・ウー 新規な抗腫瘍化合物
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
EP2100619B1 (en) 2003-02-20 2014-02-12 Seattle Genetics, Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of immune disorders
GB0303940D0 (en) 2003-02-20 2003-03-26 Pharma Mar Sau Solid phase synthesis of antitumoral compounds
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
AU2004218883B2 (en) 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
CN1761480B (zh) 2003-03-12 2012-09-26 达纳-法伯癌症协会有限公司 用于多发性骨髓瘤的治疗的aplidine
JP2006523214A (ja) 2003-03-21 2006-10-12 ジユーリー，マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
GB0314726D0 (en) 2003-06-24 2003-07-30 Inst Biomar Sa New cytotoxic depsipeptides
CN1856486A (zh) 2003-07-25 2006-11-01 诺瓦提斯公司 取代的内酰胺和它们作为抗癌剂的用途
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
ATE419242T1 (de) 2003-10-09 2009-01-15 Abbott Lab Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DE602004016376D1 (de) 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2005049030A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
DE102004011809A1 (de) 2004-03-11 2005-09-29 Robert Bosch Gmbh Magnetsensoranordnung
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
WO2005118584A2 (en) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
EP1768671A2 (en) 2004-07-09 2007-04-04 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
WO2006035244A2 (en) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
SI1827500T1 (sl) 2004-10-26 2009-10-31 Pharma Mar Sa Pegiliran liposomski doksorubicin v kombinaciji s ekteinescidinom 743
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
WO2006066183A2 (en) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
EP1879870A1 (en) 2005-05-03 2008-01-23 Pharma Mar, S.A. Antitumoral tetrahydro-pyrimidines
GB0515673D0 (en) 2005-08-01 2005-09-07 Pharma Mar Sa Antitumoral compounds
CA2617592A1 (en) 2005-08-02 2007-02-08 Pharma Mar, S.A. Genes involved in the biosynthesis of thiocoraline and heterologous production of same
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0523098D0 (en) 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
CA2630900A1 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
ES2276629B1 (es) 2005-12-15 2009-04-01 Pharma Mar, S.A. Compuestos antitumorales.
ES2288107B1 (es) 2006-01-27 2008-11-01 Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa.
HUE028055T2 (en) 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
JP2009536956A (ja) 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
PL2032551T3 (pl) 2006-06-16 2012-01-31 Pharma Mar Sa Przeciwnowotworowe związki dihydropiran-2-onu
EP2207561A2 (en) 2007-10-19 2010-07-21 Pharma Mar, S.A. Improved antitumoral treatments
JP2011500046A (ja) 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
EP2205263A1 (en) 2007-10-19 2010-07-14 Pharma Mar, S.A. Improved antitumoral treatments
EP2231695B1 (en) 2007-12-14 2013-02-13 Pharma Mar, S.A. Antitumoral compounds
US8710264B2 (en) 2007-12-20 2014-04-29 Pharma Mar, S.A. Antitumoral compounds
WO2009095480A1 (en) 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
WO2009111698A1 (en) 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved anticancer treatments
CA2717117A1 (en) 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved antitumoral treatments
NZ589269A (en) 2008-05-16 2013-03-28 Pharma Mar Sa Combination therapy with an antitumor alkaloid
KR20110028454A (ko) 2008-05-16 2011-03-18 파르마 마르 에스.에이. 다발성 골수종 치료법
UA99361C2 (uk) 2008-05-23 2012-08-10 Уайт Елелсі ТРИАЗИНИ ЯК ІНГІБІТОРИ PІ3-КІНАЗИ І mTOR
EP2321325A1 (en) 2008-07-03 2011-05-18 Pharma Mar S.A. Antitumoral macrolides
BRPI0910810A2 (pt) 2008-07-15 2019-09-24 Genentech Inc conjugados derivados de antraciclina, veículo polimérico, anticorpo, peptídeo ou proteína, veículo t-[cho]m, composições farmacêuticas, métodos de tratamento do câncer ou de distúrbios da proliferação celular, derivado de antraciclina, composto conjugado droga-anticorpo, uso, artigo de manufatura e método de produção de um composto conjugado droga-anticorpo"
MX2011000633A (es) 2008-07-17 2011-03-29 Pharma Mar Sa Compuestos anticancerigenos.
CA2745377A1 (en) 2008-12-19 2010-06-24 Pharma Mar, S.A. Anticancer compounds
WO2010149688A2 (en) 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds
EP2563803B1 (en) 2010-04-27 2016-03-09 Pharma Mar S.A. Anticancer steroidal lactones unsaturated in position 7(8)
WO2011147828A1 (en) * 2010-05-25 2011-12-01 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
KR20170096065A (ko) 2010-11-12 2017-08-23 파르마 마르 에스.에이. 항종양 알칼로이드를 이용한 병용요법
DE102012211024B4 (de) 2012-06-27 2024-10-24 Robert Bosch Gmbh Verfahren zum Betreiben eines Fahrzeuges
JP5922518B2 (ja) 2012-07-20 2016-05-24 浜松ホトニクス株式会社 シンチレータパネル及び放射線検出器
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
BR112019000589A2 (pt) 2016-07-14 2019-04-24 Pfizer Inc. pirimidina carboxamidas como inibidores da enzima vanina-1
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
HUE062032T2 (hu) 2023-09-28
JP2020517709A (ja) 2020-06-18
HRP20191443T1 (hr) 2019-11-15
KR102510975B1 (ko) 2023-03-16
PL3615544T3 (pl) 2023-07-17
ME03467B (me) 2020-01-20
HRP20191442T1 (hr) 2019-11-15
SG11201909841RA (en) 2019-11-28
US11332480B2 (en) 2022-05-17
IL295044B1 (en) 2023-07-01
JP2022130682A (ja) 2022-09-06
ES2944344T3 (es) 2023-06-20
MY198004A (en) 2023-07-25
KR20220109495A (ko) 2022-08-04
AU2022200249B1 (en) 2022-02-10
SI3395821T1 (sl) 2019-09-30
SI4047002T1 (sl) 2023-07-31
US20240166666A1 (en) 2024-05-23
AU2018260314C1 (en) 2022-04-21
JP7490835B2 (ja) 2024-05-27
DK3395820T3 (da) 2019-08-12
PL3395821T3 (pl) 2019-10-31
ES2741901T3 (es) 2020-02-12
KR102492283B1 (ko) 2023-01-27
US11713325B2 (en) 2023-08-01
PL3395820T3 (pl) 2019-11-29
PL4101855T3 (pl) 2023-12-27
AU2022201657A1 (en) 2022-03-31
CN110621678A (zh) 2019-12-27
HUE063736T2 (hu) 2024-01-28
HUE046109T2 (hu) 2020-02-28
RS59174B1 (sr) 2019-10-31
EP3395821B1 (en) 2019-05-15
ES2960063T3 (es) 2024-02-29
HRP20231233T1 (hr) 2024-01-19
MA44020A (fr) 2018-10-31
IL270153B2 (en) 2023-10-01
CY1121885T1 (el) 2020-10-14
ES2944579T3 (es) 2023-06-22
EP3395821A1 (en) 2018-10-31
KR20210126791A (ko) 2021-10-20
EP4047002A1 (en) 2022-08-24
HK1255941B (zh) 2020-04-29
JP7186723B2 (ja) 2022-12-09
US20210070775A1 (en) 2021-03-11
UY37706A (es) 2018-11-30
CN117865987A (zh) 2024-04-12
EP4101855A1 (en) 2022-12-14
EP3395820A1 (en) 2018-10-31
US20210246146A1 (en) 2021-08-12
LT3395821T (lt) 2019-08-12
EP3395820B1 (en) 2019-05-15
IL295044B2 (en) 2023-11-01
JP2018188432A (ja) 2018-11-29
PL4047002T3 (pl) 2023-07-24
IL270153B1 (en) 2023-06-01
CN114736219A (zh) 2022-07-12
HUE062157T2 (hu) 2023-10-28
JP2018188431A (ja) 2018-11-29
AU2018260314B2 (en) 2021-12-09
ME03466B (me) 2020-01-20
TW202344509A (zh) 2023-11-16
AU2018260314A1 (en) 2019-10-31
WO2018197663A1 (en) 2018-11-01
EP4101855B9 (en) 2024-01-03
DK3615544T3 (da) 2023-05-30
DK4101855T3 (da) 2023-11-06
EP4101855B1 (en) 2023-08-02
JP7422812B2 (ja) 2024-01-26
CA3061518A1 (en) 2018-11-01
CY1126061T1 (el) 2023-11-15
JOP20190254A1 (ar) 2019-10-27
MA44021B1 (fr) 2019-08-30
TWI742273B (zh) 2021-10-11
US20220242883A1 (en) 2022-08-04
SI3615544T1 (sl) 2023-07-31
DK3395821T3 (da) 2019-08-19
MX2021016054A (es) 2022-06-01
KR102491180B1 (ko) 2023-01-20
LT4047002T (lt) 2023-05-10
CN110621678B (zh) 2024-09-20
CO2019011967A2 (es) 2020-02-18
RS64174B1 (sr) 2023-05-31
KR20200012846A (ko) 2020-02-05
EP3615544B1 (en) 2023-03-22
ES2740073T3 (es) 2020-02-05
LT3615544T (lt) 2023-05-10
AU2022200249C1 (en) 2022-06-23
AU2022200250C1 (en) 2022-06-23
BR112019022282A2 (pt) 2020-05-19
EP4047002B1 (en) 2023-03-08
PT3395820T (pt) 2019-08-07
RS64200B1 (sr) 2023-06-30
SI3395820T1 (sl) 2019-09-30
IL289963B1 (en) 2023-06-01
DK4047002T3 (da) 2023-05-01
CN114751920B (zh) 2024-06-07
LT3395820T (lt) 2019-08-12
MD4101855T2 (ro) 2023-12-31
US11339180B2 (en) 2022-05-24
MD3395820T2 (ro) 2019-10-31
LT4101855T (lt) 2023-08-25
FI4047002T3 (fi) 2023-05-22
TWI807411B (zh) 2023-07-01
ECSP19083967A (es) 2019-12-27
RS64686B1 (sr) 2023-11-30
MX2019012812A (es) 2020-01-14
MD3615544T2 (ro) 2023-08-31
PT3395821T (pt) 2019-08-27
CY1121884T1 (el) 2020-10-14
MA44020B1 (fr) 2019-08-30
MD3395821T2 (ro) 2019-10-31
MD4047002T2 (ro) 2023-08-31
JP6501946B2 (ja) 2019-04-17
IL295044A (en) 2022-09-01
EP3615544B9 (en) 2024-01-03
JP2023052597A (ja) 2023-04-11
TW202202509A (zh) 2022-01-16
CL2019003057A1 (es) 2020-02-21
SG10201913300YA (en) 2020-03-30
ZA201907119B (en) 2021-07-28
HUE045641T2 (hu) 2020-01-28
CN114736219B (zh) 2024-06-07
JP6501947B2 (ja) 2019-04-17
EP3615544A1 (en) 2020-03-04
RS59173B1 (sr) 2019-10-31
IL289963A (en) 2022-03-01
FI4101855T3 (fi) 2023-09-22
US20180312529A1 (en) 2018-11-01
US10538535B2 (en) 2020-01-21
HK1255938B (zh) 2020-04-29
HRP20230433T1 (hr) 2023-07-07
MA44021A (fr) 2019-05-15
IL270153A (es) 2019-12-31
HRP20230455T1 (hr) 2023-07-21
PH12019550224A1 (en) 2020-10-12
CN114751920A (zh) 2022-07-15
FI3615544T3 (fi) 2023-05-23
TN2019000211A1 (en) 2021-01-07
IL289963B2 (en) 2023-10-01
SI4101855T1 (sl) 2024-03-29
AU2022200250B1 (en) 2022-02-10
TN2019000210A1 (en) 2021-01-07
TW201906850A (zh) 2019-02-16

Similar Documents

Publication Publication Date Title
PH12019550224A1 (en) Antitumoral compounds
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
GEP20186933B (en) Substituted dihydroisoquinoline compounds
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
GEP20207111B (en) Heteroaryl compounds for kinase inhibition
AU2018258581A8 (en) RAF-degrading conjugate compounds
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
PH12015502410A1 (en) Biheteroaryl compounds and uses thereof
MX2015001720A (es) Hetero-azepinonas sustituidas.
NZ710444A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
GEP20186893B (en) Pyrazines modulators of gpr6
MX2020005707A (es) Profarmacos de creatina, composiciones y metodos de uso de estos.
WO2018211324A8 (en) Prodrugs for the treatment of disease
WO2018146390A8 (fr) Utilisation d'un compose appartenant a la famille des diuretiques pour traiter le cancer
EA201992557A1 (ru) Противоопухолевые соединения
IN2013DE03665A (es)
UA90817U (uk) Сполука 1,1-діетилкарбокси-2-трифторметил-2-(5'-бромуридил-1'-)етилен з потенційними фізіологічними властивостями
UA90821U (uk) Сполука 1-1-діетилкарбоксі-2-ізопропокси-2-трифторметилетилен з потенційними фізіологічними властивостями
UA91886U (uk) 1-трет-бутокси-3-(2,2,6,6-тетраметил-4-гідроксипіперидино)-2-пропанол